Arun A Bio, Inc. announced it raised $13.3 Million in an initial filing from an offering of $13.3 Million

Company

Location

About

ArunA Bio is developing a new class of biologics targeting multiple CNS disorders with an initial focus on treatments for patients with stroke, traumatic brain and spinal cord injuries. In multiple preclinical studies we have demonstrated that enhancing the nervous systems' self-repair mechanisms translate into structural and functional benefits. Leveraging our extensive experience producing neural-derived exosomes through a proprietary, scalable manufacturing process we are advancing towards multiple clinical programs.